About Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200
Debt
Debt-to-Equity Ratio0.02%
Current Ratio12.23%
Quick Ratio12.23%
Price-To-Earnings
Trailing P/E Ratio-17.75
Forward P/E Ratio-13.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$89.91 million
Price / Sales107.17
Cash FlowN/A
Price / CashN/A
Book Value$17.96 per share
Price / Book5.36
Profitability
EPS (Most Recent Fiscal Year)($5.42)
Net Income$-490,870,000.00
Net Margins-545.95%
Return on Equity-41.08%
Return on Assets-33.16%
Miscellaneous
Employees749
Outstanding Shares100,170,000
Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, February, 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.38) by $0.10. The biopharmaceutical company had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm's quarterly revenue was up 116.6% on a year-over-year basis. During the same period in the previous year, the business posted ($1.32) EPS. View Alnylam Pharmaceuticals' Earnings History.
When is Alnylam Pharmaceuticals' next earnings date?
What price target have analysts set for ALNY?
21 analysts have issued twelve-month price objectives for Alnylam Pharmaceuticals' shares. Their forecasts range from $56.00 to $207.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $139.3333 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.
What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alnylam reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and an action date of Aug 11, 2018 as set by the FDA. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. Stiff competition remains a threat as well. Estimates have remained stable ahead of the Q1 earnings results." (4/17/2018)
- 2. Chardan Capital analysts commented, "We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations." (1/19/2018)
- 3. FBR & Co analysts commented, "We are initiating coverage of Alnylam Pharmaceuticals, Inc. (ALNY), making it our Alpha Generator pick, with a Buy rating and a 12-month price target of $150 per share, due to our utmost conviction that Alnylam represents a foundational biopharma investment, led by the firm’s hereditary transthyretin amyloidosis (hATTR) franchise." (10/30/2017)
- 4. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Nektar Therapeutics (NKTR), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Genmab As (GNMSF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), SAGE Therapeutics (SAGE), Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO) and Gal�pagos (GLPG).
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Michael W. Bonney, Independent Chairman of the Board (Age 58)
- Barry E. Greene, President (Age 53)
- John M. Maraganore Ph.D., Chief Executive Officer, Director (Age 54)
- Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer (Age 39)
- Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President (Age 54)
- Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development (Age 54)
- Laurie B. Keating, Senior Vice President, General Counsel, Secretary (Age 62)
- Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
- Theresa Heggie, Senior Vice President, Head of Europe and Canada (Age 57)
- Peter F. Smith Ph.D., Senior Vice President - Early Development (Age 59)
Has Alnylam Pharmaceuticals been receiving favorable news coverage?
News coverage about ALNY stock has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a news impact score of 0.22 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Alnylam Pharmaceuticals' major shareholders?
Alnylam Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include
FMR LLC
(15.00%) and
FMR LLC
(15.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, David E I Pyott, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
How do I buy shares of Alnylam Pharmaceuticals?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of ALNY stock can currently be purchased for approximately $96.19.
How big of a company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a market capitalization of $9.79 billion and generates $89.91 million in revenue each year. The biopharmaceutical company earns $-490,870,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Alnylam Pharmaceuticals employs 749 workers across the globe.
How can I contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]
MarketBeat Community Rating for Alnylam Pharmaceuticals (ALNY)
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
21 Wall Street analysts have issued ratings and price targets for Alnylam Pharmaceuticals in the last 12 months. Their average twelve-month price target is $139.3333, suggesting that the stock has a possible upside of 44.85%. The high price target for ALNY is $207.00 and the low price target for ALNY is $56.00. There are currently 3 sell ratings, 3 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.62 | 2.59 | 2.59 | 2.48 |
| Ratings Breakdown: | 3 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s) | 3 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s) | 3 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s) | 3 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $139.3333 | $131.3810 | $125.1429 | $102.90 |
| Price Target Upside: | 44.85% upside | 7.50% downside | 0.93% upside | 12.42% downside |
Alnylam Pharmaceuticals (NASDAQ:ALNY) Consensus Price Target History
Alnylam Pharmaceuticals (NASDAQ:ALNY) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Alnylam Pharmaceuticals (NASDAQ:ALNY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 92.00%
Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/26/2018 | Yvonne Greenstreet | COO | Sell | 7,221 | $136.54 | $985,955.34 | 7,221 |  |
| 3/20/2018 | Laurie Keating | SVP | Sell | 1,562 | $149.83 | $234,034.46 | 16,062 | |
| 3/14/2018 | Akshay Vaishnaw | Insider | Sell | 88,554 | $143.10 | $12,672,077.40 | 55,856 | |
| 3/14/2018 | Barry E Greene | President | Sell | 38,460 | $143.10 | $5,503,626.00 | 97,544 | |
| 3/13/2018 | Laurie Keating | SVP | Sell | 20,000 | $145.00 | $2,900,000.00 | 24,500 | |
| 3/13/2018 | Paul Schimmel | Director | Sell | 27,823 | $150.00 | $4,173,450.00 | 10,000 | |
| 3/9/2018 | Philip A Sharp | Director | Sell | 15,000 | $129.00 | $1,935,000.00 | 155,795 | |
| 1/4/2018 | Michael Mason | VP | Sell | 36,745 | $131.59 | $4,835,274.55 | 6,352 | |
| 12/20/2017 | Laurie Keating | SVP | Sell | 6,249 | $121.20 | $757,378.80 | 17,749 | |
| 12/1/2017 | Laurie Keating | SVP | Sell | 30,000 | $135.89 | $4,076,700.00 | 41,500 | |
| 11/22/2017 | John Maraganore | CEO | Sell | 73,415 | $130.90 | $9,610,023.50 | 223,125 | |
| 11/15/2017 | John Maraganore | CEO | Sell | 74,000 | $126.86 | $9,387,640.00 | 223,710 | |
| 11/2/2017 | Dennis A Ausiello | Director | Sell | 20,000 | $130.00 | $2,600,000.00 | 20,000 | |
| 10/30/2017 | Akshay Vaishnaw | EVP | Sell | 33,666 | $121.46 | $4,089,072.36 | 45,201 | |
| 10/2/2017 | Barry E Greene | President | Sell | 85,316 | $125.00 | $10,664,500.00 | | |
| 9/20/2017 | Barry E Greene | President | Sell | 76,815 | $100.00 | $7,681,500.00 | 165,399 | |
| 5/31/2017 | Sanofi | Major Shareholder | Buy | 297,501 | $71.87 | $21,381,396.87 | | |
| 5/30/2017 | Laurie Keating | SVP | Buy | 11,500 | $65.35 | $751,525.00 | 11,500 | |
| 5/23/2017 | Akshay Vaishnaw | EVP | Sell | 11,000 | $75.00 | $825,000.00 | 21,297 | |
| 5/16/2017 | Michael Mason | VP | Sell | 9,375 | $70.00 | $656,250.00 | 5,625 | |
| 5/15/2017 | Akshay Vaishnaw | SVP | Sell | 43,750 | $65.00 | $2,843,750.00 | 43,047 | |
| 1/25/2017 | Philip A Sharp | Director | Sell | 15,000 | $37.95 | $569,250.00 | 155,795 | |
| 1/18/2017 | Philip A Sharp | Director | Sell | 15,000 | $37.83 | $567,450.00 | 155,795 | |
| 11/30/2016 | Akshay Vaishnaw | CMO | Sell | 29,165 | $44.99 | $1,312,133.35 | 34,915 | |
| 10/13/2016 | David E I Pyott | Director | Buy | 27,900 | $37.00 | $1,032,300.00 | | |
| 7/20/2016 | John Maraganore | CEO | Sell | 30,151 | $64.69 | $1,950,468.19 | 148,465 | |
| 4/20/2016 | John Maraganore | CEO | Sell | 30,151 | $67.46 | $2,033,986.46 | 148,465 | |
| 3/9/2016 | Michael W Bonney | Director | Buy | 2,000 | $58.36 | $116,720.00 | | |
| 2/22/2016 | David-Alexandre C Gros | SVP | Buy | 1,000 | $62.75 | $62,750.00 | 100 | |
| 2/1/2016 | Sanofi | Major Shareholder | Buy | 205,030 | $69.75 | $14,300,842.50 | | |
| 1/20/2016 | John Maraganore | CEO | Sell | 30,152 | $71.78 | $2,164,310.56 | 133,389 | |
| 12/4/2015 | Philip A. Sharp | Director | Sell | 30,000 | $109.00 | $3,270,000.00 | 140,795 | |
| 12/2/2015 | John Maraganore | CEO | Sell | 58,689 | $104.87 | $6,154,715.43 | 133,389 | |
| 11/20/2015 | John Maraganore | CEO | Sell | 58,690 | $102.88 | $6,038,027.20 | 133,389 | |
| 11/12/2015 | Kevin P. Starr | Director | Sell | 75,000 | $103.89 | $7,791,750.00 | | |
| 6/16/2015 | Akshay Vaishnaw | CMO | Sell | 8,750 | $128.83 | $1,127,262.50 | | |
| 5/12/2015 | Michael W Bonney | Director | Buy | 2,000 | $112.16 | $224,320.00 | | |
| 4/21/2015 | Paul Schimmel | Director | Sell | 10,000 | $130.02 | $1,300,200.00 | | |
| 3/19/2015 | Dennis A Ausiello | Director | Sell | 5,000 | $120.00 | $600,000.00 | | |
| 3/17/2015 | Akshay Vaishnaw | CMO | Sell | 8,750 | $116.86 | $1,022,525.00 | | |
| 1/29/2015 | Sanofi | Major Shareholder | Buy | 97,118 | $95.00 | $9,226,210.00 | | |
| 1/26/2015 | John Maraganore | CEO | Buy | 10,000 | $95.00 | $950,000.00 | | |
| 1/26/2015 | Steven M Paul | Director | Buy | 1,000 | $95.00 | $95,000.00 | | |
| 12/19/2014 | Barry E Greene | COO | Sell | 11,200 | $100.00 | $1,120,000.00 | | |
| 12/16/2014 | Akshay Vaishnaw | EVP | Sell | 10,626 | $93.60 | $994,593.60 | | |
| 12/15/2014 | Michael Mason | VP | Sell | 22,162 | $97.50 | $2,160,795.00 | | |
| 11/18/2014 | Laurence Reid | SVP | Sell | 10,000 | $90.67 | $906,700.00 | | |
| 11/17/2014 | Barry E Greene | COO | Sell | 33,200 | $89.63 | $2,975,716.00 | | |
| 10/28/2014 | Paul Schimmel | Director | Sell | 15,000 | $95.00 | $1,425,000.00 | | |
| 10/22/2014 | Dennis A Ausiello | Director | Sell | 5,000 | $90.00 | $450,000.00 | | |
| 10/13/2014 | Philip A Sharp | Director | Sell | 110,000 | $85.00 | $9,350,000.00 | | |
| 9/25/2014 | Kevin P Starr | Director | Sell | 90,000 | $78.09 | $7,028,100.00 | | |
| 9/24/2014 | Kevin P Starr | Director | Sell | 45,000 | $79.08 | $3,558,600.00 | | |
| 9/18/2014 | John Maraganore | CEO | Sell | 113,668 | $77.71 | $8,833,140.28 | | |
| 9/16/2014 | Akshay Vaishnaw | EVP | Sell | 10,625 | $72.04 | $765,425.00 | | |
| 8/18/2014 | Laurence Reid | SVP | Sell | 13,500 | $67.34 | $909,090.00 | | |
| 6/26/2014 | John Maraganore | CEO | Sell | 113,668 | $65.45 | $7,439,570.60 | | |
| 6/17/2014 | Akshay Vaishnaw | EVP | Sell | 10,625 | $69.82 | $741,837.50 | | |
| 5/21/2014 | John Clarke | Director | Sell | 35,000 | $53.80 | $1,883,000.00 | | |
| 5/19/2014 | Laurence Reid | SVP | Sell | 13,500 | $57.83 | $780,705.00 | 3,905 | |
| 5/15/2014 | John Maraganore | CEO | Sell | 113,668 | $56.73 | $6,448,385.64 | 106,320 | |
| 3/25/2014 | Sanofi | major shareholder | Buy | 344,448 | $66.88 | $23,036,682.24 | | |
| 3/18/2014 | Akshay Vaishnaw | EVP | Sell | 32,769 | $73.95 | $2,423,267.55 | | |
| 2/19/2014 | Laurence Reid | SVP | Sell | 20,400 | $80.06 | $1,633,224.00 | 3,905 | |
| 1/24/2014 | Akshay Vaishnaw | EVP | Sell | 7,890 | $85.75 | $676,567.50 | | |
| 1/13/2014 | Paul Schimmel | Director | Sell | 15,000 | $85.36 | $1,280,400.00 | | |
| 12/20/2013 | Paul Schimmel | Director | Sell | 15,000 | $65.00 | $975,000.00 | | |
| 12/17/2013 | Akshay Vaishnaw | EVP | Sell | 33,480 | $60.72 | $2,032,905.60 | 12,588 | |
| 10/22/2013 | Paul Schimmel | Director | Sell | 15,000 | $60.00 | $900,000.00 | | |
| 9/11/2013 | John Maraganore | CEO | Sell | 58,947 | $55.50 | $3,271,558.50 | | |
| 9/10/2013 | Akshay Vaishnaw | EVP | Sell | 6,250 | $57.48 | $359,250.00 | | |
| 8/14/2013 | John Maraganore | CEO | Sell | 60,000 | $48.97 | $2,938,200.00 | 18,617 | |
| 7/12/2013 | Michael Mason | VP | Sell | 14,200 | $50.00 | $710,000.00 | | |
| 7/10/2013 | John Maraganore | CEO | Sell | 60,000 | $37.11 | $2,226,600.00 | | |
| 7/1/2013 | Michael Mason | VP | Sell | 27,000 | $32.00 | $864,000.00 | | |
| 6/17/2013 | Michael Mason | VP | Sell | 23,625 | $29.93 | $707,096.25 | | |
| 6/11/2013 | Akshay Vaishnaw | EVP | Sell | 15,000 | $31.08 | $466,200.00 | | |
| 5/28/2013 | Barry E Greene | COO | Sell | 22,822 | $30.00 | $684,660.00 | | |
| 5/28/2013 | Laurence Reid | SVP | Sell | 5,000 | $30.00 | $150,000.00 | | |
| 3/26/2013 | Kevin P Starr | Director | Sell | 52,631 | $23.49 | $1,236,302.19 | | |
| 1/22/2013 | Philip A Sharp | Director | Buy | 4,967 | $20.13 | $99,985.71 | | |
(Data available from 1/1/2013 forward)
Alnylam Pharmaceuticals (NASDAQ ALNY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Credit Suisse Group Analysts Give Alnylam Pharmaceuticals (ALNY) a $96.00 Price Target
www.americanbankingnews.com - April 19 at 12:16 PM |
| Alnylam Pharmaceuticals (ALNY) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:30 PM |
 | Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'
www.benzinga.com - April 18 at 5:17 PM |
 | Your Daily Pharma Scoop: GW Pharmaceuticals' Epidiolex, Alnylam Data, Johnson & Johnson's Q1 Results
seekingalpha.com - April 18 at 8:50 AM |
| Ladenburg Thalmann Analysts Give Alnylam Pharmaceuticals (ALNY) a $90.00 Price Target
www.americanbankingnews.com - April 17 at 11:58 PM |
 | Alnylam Pharma (ALNY) Announces New Positive Clinical Results for Givosiran
www.streetinsider.com - April 17 at 5:27 PM |
| Alnylam Pharmaceuticals (ALNY) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 17 at 12:47 PM |
 | Trade secrets battle between Alnylam, Dicerna is just one of many
www.msn.com - April 17 at 9:08 AM |
| Alnylam Pharmaceuticals (ALNY) Disease Background & Givosiran New Clinical Results - Slideshow
seekingalpha.com - April 16 at 4:57 PM |
| Alnylam down 3% on early-stage givosiran data in AHP
seekingalpha.com - April 16 at 4:57 PM |
| Alnylam Pharmaceuticals (ALNY) Now Covered by Analysts at Sanford C. Bernstein
www.americanbankingnews.com - April 15 at 4:30 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 3:35 PM |
| Zacks: Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) Will Announce Quarterly Sales of $35.98 Million
www.americanbankingnews.com - April 13 at 4:06 AM |
 | Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
finance.yahoo.com - April 11 at 5:02 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Post Earnings of -$1.18 Per Share
www.americanbankingnews.com - April 11 at 8:09 AM |
| Morgan Stanley Raises Alnylam Pharmaceuticals (ALNY) Price Target to $50.00
www.americanbankingnews.com - April 10 at 8:24 PM |
| Alnylam Pharmaceuticals (ALNY) PT Raised to $130.00 at Jefferies Group
www.americanbankingnews.com - April 8 at 8:06 PM |
| Alnylam Pharmaceuticals (ALNY) Upgraded by Goldman Sachs to Buy
www.americanbankingnews.com - April 8 at 3:42 PM |
| See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
finance.yahoo.com - April 6 at 9:01 AM |
| BidaskClub Lowers Alnylam Pharmaceuticals (ALNY) to Sell
www.americanbankingnews.com - April 5 at 10:26 AM |
| Alnylam Pharmaceuticals (ALNY) Now Covered by FBR & Co
www.americanbankingnews.com - April 4 at 3:32 PM |
| Alnylam Pharmaceuticals (ALNY) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 8:10 PM |
| With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip
finance.yahoo.com - April 3 at 8:57 AM |
| Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - April 2 at 5:18 PM |
 | Alnylam Falls on Pfizer's Rare Disease Drug Success
www.zacks.com - April 2 at 5:02 PM |
| Alnylam and Ionis continue down moves
seekingalpha.com - April 2 at 5:02 PM |
| Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - April 2 at 3:16 PM |
| Alnylam Pharmaceuticals (ALNY) Now Covered by B. Riley
www.americanbankingnews.com - April 2 at 2:04 PM |
| Barclays Increases Alnylam Pharmaceuticals (ALNY) Price Target to $158.00
www.americanbankingnews.com - April 1 at 11:23 AM |
| B. Riley Cuts Alnylam Pharmaceuticals (ALNY) Price Target to $220.00
www.americanbankingnews.com - April 1 at 10:34 AM |
| Alnylam Pharmaceuticals (ALNY) Upgraded at JPMorgan Chase
www.americanbankingnews.com - March 31 at 8:16 PM |
| Morgan Stanley Raises Alnylam Pharmaceuticals (ALNY) Price Target to $130.00
www.americanbankingnews.com - March 31 at 5:28 PM |
| Alnylam Pharma (ALNY) Announces New Clinical Results from the APOLLO Phase 3 Study of Patisiran
www.streetinsider.com - March 30 at 8:53 AM |
| Alnylam and Ionis in the red on positive late-stage data on Pfizer's amyloidosis drug tafamidis
seekingalpha.com - March 29 at 5:02 PM |
| Alnylam Pharmaceuticals, Inc. (ALNY) COO Yvonne Greenstreet Sells 7,221 Shares
www.americanbankingnews.com - March 28 at 10:31 PM |
| Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation
www.msn.com - March 28 at 4:56 PM |
| Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)
finance.yahoo.com - March 28 at 4:56 PM |
| Alnylam Pharmaceuticals (ALNY) Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 11:54 AM |
| Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
finance.yahoo.com - March 28 at 9:03 AM |
| Alnylam Pharmaceuticals (ALNY) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - March 28 at 8:05 AM |
| Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Post Quarterly Sales of $38.81 Million
www.americanbankingnews.com - March 27 at 5:40 AM |
| Alnylam Pharmaceuticals (ALNY) Price Target Increased to $207.00 by Analysts at JMP Securities
www.americanbankingnews.com - March 26 at 10:49 AM |
| Alnylam Pharma (ALNY) Receives EMA PRIME Designation for Accelerated Assessment of Lumasiran
www.streetinsider.com - March 26 at 9:03 AM |
 | Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary ...
www.businesswire.com - March 26 at 9:03 AM |
| Alnylam receives EMA's PRIME designation for assessment of Lumasiran for the treatment of PH1
seekingalpha.com - March 26 at 9:03 AM |
| Gilead Sciences' Investors Better Watch This Regeneron-Alnylam Deal
finance.yahoo.com - March 24 at 4:54 PM |
| Biotech Analysis Central Pharma News: Regeneron And Alnylam Team Up, Zealand's Rescue Pen Succeeds, AbbVie's Hope Remains With Rova-T Prospects
seekingalpha.com - March 24 at 4:54 PM |
| Insider Selling: Alnylam Pharmaceuticals, Inc. (ALNY) SVP Sells 1,562 Shares of Stock
www.americanbankingnews.com - March 22 at 7:33 PM |
| Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam
finance.yahoo.com - March 22 at 5:09 PM |
| Regeneron (REGN) and Alnylam (ALNY) Announce Pact to Discover New Treatments for NASH
www.streetinsider.com - March 22 at 9:01 AM |
Alnylam Pharmaceuticals (NASDAQ:ALNY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Income Statement, Balance Sheet and Cash Flow Statement
Alnylam Pharmaceuticals (NASDAQ ALNY) Stock Chart for Friday, April, 20, 2018
Loading chart…
